SSY Group (HKG:2005) said that China's National Medical Products Administration approved two of its products, Vonoprazan Fumarate and Dronedarone Hydrochloride, for registration to become a bulk drug for preparations on the market, according to a Monday filing with the Hong Kong bourse.
Vonoprazan Fumarate is mainly used to treat reflux esophagitis, while Dronedarone Hydrochloride is an antiarrhythmic drug, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments